NCT01275196View on ClinicalTrials.gov

Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Nilotinib

DRUG

Imatinib

Trial Locations (12)

100044

Novartis Investigative Site, Beijing

200025

Novartis Investigative Site, Shanghai

200433

Novartis Investigative Site, Shanghai

210008

Novartis Investigative Site, Nanjing

250012

Novartis Investigative Site, Jinan

300020

Novartis Investigative Site, Tianjin

310003

Novartis Investigative Site, Hangzhou

350001

Novartis Investigative Site, Fuzhou

430022

Novartis Investigative Site, Wuhan

510080

Novartis Investigative Site, Guangzhou

510515

Novartis Investigative Site, Guangzhou

610041

Novartis Investigative Site, Chengdu

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY